Recent News

• 09.10.2025 - Bioxcel Therapeutics SERENITY At-Home Pivotal Phase 3 Safety Trial Results
• 09.10.2025 - Bioxcel Therapeutics SERENITY At-Home Pivotal Phase 3 Safety Trial Results
• 09.10.2025 - BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
• 09.10.2025 - BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
• 09.10.2025 - BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 09.04.2025 - BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Recent Filings

• 09.10.2025 - 8-K Current report
• 09.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.27.2025 - 8-K Current report